Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19
Arturo Casadevall, Liise‐anne Pirofski, Michael J. Joyner
mBio (2021) Vol. 12, Iss. 2
Open Access | Times Cited: 77

Showing 26-50 of 77 citing articles:

Expanding the Pathogenic Potential Concept To Incorporate Fulminancy, Time, and Virulence Factors
Arturo Casadevall
mSphere (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 12
COVID-19 Serology Data Provide Guidance for Future Deployments of Convalescent Plasma
David J. Sullivan, Arturo Casadevall
mBio (2023) Vol. 14, Iss. 3
Open Access | Times Cited: 7
The fossilization of randomized clinical trials
Nigel Paneth, Michael J. Joyner, Arturo Casadevall
Journal of Clinical Investigation (2022) Vol. 132, Iss. 4
Open Access | Times Cited: 11
Bamlanivimab for Prevention of COVID-19
Daniel R. Kuritzkes
JAMA (2021) Vol. 326, Iss. 1, pp. 31-31
Closed Access | Times Cited: 14
COVID-19 convalescent plasma for the treatment of immunocompromised patients: a systematic review
Jonathon W. Senefeld, Massimo Franchini, Carlo Mengoli, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 10
Convalescent plasma and COVID‐19: Time for a second—second look?
Michael J. Joyner, Rickey E. Carter, DeLisa Fairweather, et al.
Transfusion Medicine (2022) Vol. 33, Iss. 1, pp. 16-20
Open Access | Times Cited: 10
Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection
Entao Li, Qiuxue Han, Jinhao Bi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
T-cell immunity to SARS-CoV-2: what if the known best is not the optimal course for the long run? Adapting to evolving targets
Alexandre E. Nowill, Manuel Caruso, Pedro O. de Campos‐Lima
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Estimated Health Outcomes and Costs of COVID-19 Prophylaxis With Monoclonal Antibodies Among Unvaccinated Household Contacts in the US
Abraham D. Flaxman, Rodal Issema, Ruanne V. Barnabas, et al.
JAMA Network Open (2022) Vol. 5, Iss. 4, pp. e228632-e228632
Open Access | Times Cited: 9
Control of complement-induced inflammatory responses to SARS-CoV-2 infection by anti-SARS-CoV-2 antibodies
Marta Bermejo‐Jambrina, Lieve E. H. van der Donk, John L. van Hamme, et al.
The EMBO Journal (2024) Vol. 43, Iss. 7, pp. 1135-1163
Open Access | Times Cited: 1
AAV-vectored expression of monospecific or bispecific monoclonal antibodies protects mice from lethal Pseudomonas aeruginosa pneumonia
Jordyn A. Lopes, Nicole Garnier, Yanlong Pei, et al.
Gene Therapy (2024) Vol. 31, Iss. 7-8, pp. 400-412
Closed Access | Times Cited: 1
Efficacy of convalescent plasma in hospitalized COVID-19 patients: findings from a controlled trial
Tânia Portella Costa, Mateus Nóbrega Aoki, Camilla Moreira Ribeiro, et al.
Brazilian Journal of Medical and Biological Research (2024) Vol. 57
Open Access | Times Cited: 1
Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients
Juanjie Tang, Gabrielle Grubbs, Youri Lee, et al.
Clinical Infectious Diseases (2021) Vol. 74, Iss. 2, pp. 327-334
Open Access | Times Cited: 12
Exercise and Experiments of Nature
Michael J. Joyner, Chad C. Wiggins, Sarah E. Baker, et al.
Comprehensive physiology (2023), pp. 4879-4907
Closed Access | Times Cited: 4
Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19
Alberto Alape‐Girón, Andrés Moreira‐Soto, Mauricio Arguedas, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 11
In vitro Characterization of Anti-SARS-CoV-2 Intravenous Immunoglobulins (IVIg) Produced From Plasma of Donors Immunized With the BNT162b2 Vaccine and Its Comparison With a Similar Formulation Produced From Plasma of COVID-19 Convalescent Donors
Gabriel Rojas-Jiménez, Daniela Solano, Álvaro Segura, et al.
Frontiers in Medical Technology (2022) Vol. 3
Open Access | Times Cited: 7
WHO covid-19 drugs guideline: reconsider using convalescent plasma
Nigel Paneth, Arturo Casadevall, Liise-anne Pirofski, et al.
BMJ (2022), pp. o295-o295
Closed Access | Times Cited: 7
Convalescent Plasma Use in the United States was inversely correlated with COVID-19 Mortality: Did Plasma Hesitancy cost lives?
Arturo Casadevall, Quigly Dragotakes, Patrick W. Johnson, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 10
Pharmacokinetics and Efficacy of Human Hyperimmune Intravenous Immunoglobulin Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Adult Syrian Hamsters
Charles B. Stauft, Million A. Tegenge, Surender Khurana, et al.
Clinical Infectious Diseases (2021) Vol. 75, Iss. 1, pp. e459-e465
Open Access | Times Cited: 9
Frontline Physician Perspectives on Their Experiences Working During the First Wave of the COVID-19 Pandemic
Cristina M. González, Onjona B. Hossain, Monica E. Peek
Journal of General Internal Medicine (2022) Vol. 37, Iss. 16, pp. 4233-4240
Open Access | Times Cited: 6
Clinical profile, antifungal susceptibility, and molecular characterization of Candida auris isolated from patients in a South Indian surgical ICU.
S. Umamaheshwari, Sumana Mahadevaiah Neelambike, Shamanth A. Shankarnarayan, et al.
Journal de Mycologie Médicale (2021) Vol. 31, Iss. 4, pp. 101176-101176
Closed Access | Times Cited: 8
COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacy
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 7
Patient-Derived Antibody Data Yields Development of Broadly Cross-Protective Monoclonal Antibody against ST258 Carbapenem-ResistantKlebsiella pneumoniae
Kasturi Banerjee, Michael P. Motley, Camila Boniche-Alfaro, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 4
Open Access | Times Cited: 5
Late Administration and Corticosteroid Usage Explain Inefficacy in COVID-19 Convalescent Plasma Trial
Arturo Casadevall, David J. Sullivan
The Journal of Infectious Diseases (2023) Vol. 229, Iss. 2, pp. 617-618
Open Access | Times Cited: 2
Reduced neutralization of SARS-CoV-2 variants by convalescent plasma and hyperimmune intravenous immunoglobulins for treatment of COVID-19
Juanjie Tang, Youri Lee, Supriya Ravichandran, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 6

Scroll to top